Jianhong Li, Cynthia L Jackson, Dongfang Yang, Lelia Noble, Michael Wheeler, Dolores MacKenzie, Temitope Adegun, Ali Amin
Invasive micropapillary urothelial carcinomas (MPUC) emerge at higher stages and follow a more aggressive course than conventional invasive urothelial carcinomas (UC). Little is known about the target therapies using tyrosine kinase inhibitors in MPUC. This study is to investigate potential effectiveness of tyrosine kinase receptor inhibitors by determining expression of epidermal growth factor receptor (EGFR), human epidermal receptor 2 (HER2), and vascular endothelial growth factor receptor 2 (VEGFR) proteins in MPUC and UC. 16 cases of MPUC and 16 stage-matched UC were identified. Immunohistochemistry for EGFR, HER2, and VEGFR2 and HER2 gene amplification by fluorescence in situ hybridization (FISH) were performed. HER2 and EGFR proteins were expressed in MPUC and UC, with significantly higher HER2 expression in MPUC (ratio 1.82, p < 0.01). HER2 gene amplification was identified in 4 of 16 MPUC (25 %). Amplification was limited to cases with 3+ HER2 expression (100% concordance). EGFR expression in MPUC was slightly higher than UC but not statistically significant (ratio 1.57, p = 0.19). EGFR and HER2 coexpression was noted in 75% of MPUC and 37.5% of UC. No VEGFR expression was identified in the urothelium. Strong VEGFR expression was noted in stromal vessels in both MPUC and UC. In conclusion, EGFR and HER2 are potential targets for neoadjuvant chemotherapy in MPUC and UC. There is no direct anti-tumor effect expected for VEGFR inhibitors.
Urology. 2004 Apr;63(4):786-90
[PMID:
15072912]
Mod Pathol. 2011 Aug;24(8):1111-9
[PMID:
21516078]
Eur J Cancer. 2006 Oct;42(15):2660-1
[PMID:
16934972]
Virchows Arch. 2004 May;444(5):415-9
[PMID:
15029496]
Oncol Rep. 2007 Jul;18(1):3-7
[PMID:
17549338]
Urol Int. 2009;82(3):312-7
[PMID:
19440020]
BioDrugs. 2009;23(6):377-89
[PMID:
19894779]
J Urol. 2006 Apr;175(4):1245-52
[PMID:
16515971]
Clin Adv Hematol Oncol. 2012 Aug;10(8):504-16
[PMID:
23073049]
Mol Cell Biol. 1998 Sep;18(9):5042-51
[PMID:
9710588]
N Engl J Med. 2003 Aug 28;349(9):859-66
[PMID:
12944571]
J Clin Oncol. 2010 Mar 10;28(8):1373-9
[PMID:
20142593]
Urology. 2011 Apr;77(4):867-70
[PMID:
21296399]
Oncol Rep. 2010 Jun;23(6):1577-83
[PMID:
20428812]
Mod Pathol. 2009 Jun;22 Suppl 2:S96-S118
[PMID:
19494856]
Anticancer Res. 1997 Mar-Apr;17(2B):1293-6
[PMID:
9137488]
Mol Cancer Ther. 2006 May;5(5):1280-9
[PMID:
16731761]
Urol J. 2007 Summer;4(3):151-4
[PMID:
17987577]
Mod Pathol. 2009 May;22(5):660-7
[PMID:
19270645]
J Urol. 2006 Mar;175(3 Pt 1):881-5
[PMID:
16469571]
J BUON. 2009 Jul-Sep;14(3):457-62
[PMID:
19810139]
Am J Surg Pathol. 1994 Dec;18(12):1224-32
[PMID:
7977945]
Hum Pathol. 2010 Aug;41(8):1159-64
[PMID:
20381120]
Clin Cancer Res. 2001 Aug;7(8):2440-7
[PMID:
11489824]
Korean J Urol. 2011 Dec;52(12):815-8
[PMID:
22216392]
Histopathology. 2003 Sep;43(3):272-9
[PMID:
12940780]
Cancer. 2009 Jul 1;115(13):2881-90
[PMID:
19399906]
Adv Urol. 2012;2012:181964
[PMID:
22991510]
Nat Rev Cancer. 2007 Mar;7(3):169-81
[PMID:
17318210]
Oncol Rep. 2008 Jan;19(1):57-63
[PMID:
18097576]
Adv Anat Pathol. 2010 May;17(3):182-6
[PMID:
20418672]
Hum Pathol. 2012 Oct;43(10):1590-5
[PMID:
22406363]
Am J Surg Pathol. 2010 Sep;34(9):1367-76
[PMID:
20717002]
Adv Anat Pathol. 2004 Nov;11(6):297-303
[PMID:
15505530]
BJU Int. 2010 Oct;106(8):1216-22
[PMID:
20089105]
Cancer. 2013 Feb 1;119(3):540-7
[PMID:
22914978]
J Clin Oncol. 2007 Jun 1;25(16):2218-24
[PMID:
17538166]
Hum Pathol. 2012 Dec;43(12):2124-8
[PMID:
22939957]
J Clin Oncol. 2007 Mar 1;25(7):884-96
[PMID:
17327610]
Cancer. 2007 Jul 1;110(1):62-7
[PMID:
17542024]
Urol Oncol. 2009 Jul-Aug;27(4):391-9
[PMID:
18534874]
Urol Oncol. 2014 Aug;32(6):826-32
[PMID:
24931270]
Pathol Oncol Res. 2008 Sep;14(3):261-6
[PMID:
18415713]
Histopathology. 2004 Jul;45(1):55-64
[PMID:
15228444]
J Clin Oncol. 2013 Feb 20;31(6):724-30
[PMID:
23341513]
Pathol Res Pract. 2009;205(12):807-10
[PMID:
19767154]
Clin Cancer Res. 2014 Jan 1;20(1):68-75
[PMID:
24192927]
J Natl Cancer Inst. 2002 Sep 4;94(17):1320-9
[PMID:
12208897]
Am J Transl Res. 2011 Aug 15;3(4):362-73
[PMID:
21904656]
J Clin Endocrinol Metab. 1985 Nov;61(5):997-1000
[PMID:
3876350]
J Clin Oncol. 2011 Jun 1;29(16):2171-7
[PMID:
21502557]
Int J Surg Pathol. 2009 Jun;17(3):198-205
[PMID:
19443884]
BJU Int. 2013 Jun;111(8):E325-30
[PMID:
23384236]
Aged
Aged, 80 and over
Antineoplastic Agents
Biomarkers, Tumor
Carcinoma, Papillary
Cohort Studies
ErbB Receptors
Female
Gene Expression Regulation, Neoplastic
Humans
Immunohistochemistry
In Situ Hybridization, Fluorescence
Male
Middle Aged
Neoplasm Invasiveness
Receptor, ErbB-2
Urinary Bladder Neoplasms
Urothelium
Vascular Endothelial Growth Factor Receptor-2
